-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has received approval for the active pharmaceutical ingredients of pentoxifylline, levonidazole, and ornidazole.
Category:
Time：2022-05-27
Recently, three active pharmaceutical ingredients—pentoxifylline, levonidazole, and ornidazole—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, have been approved by the National Medical Products Administration and can now be officially used in marketed pharmaceutical preparations.
During the Li Xia season, Shijiazhuang No.4 Pharmaceutical Group’s R&D and innovation efforts are entering a harvest period. Recently, three active pharmaceutical ingredients—pentoxifylline, levonidazole, and ornidazole—submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang No.4 Pharmaceutical Group, have been approved by the National Medical Products Administration and can now be officially used in marketed formulations. Among these, pentoxifylline is the second domestic pharmaceutical company to receive approval, while levonidazole is the third.
It is reported that pentoxifylline preparations are primarily used to treat peripheral vascular diseases and cerebral vascular insufficiency. Levonidazole and ornidazole preparations are mainly used to treat various infections caused by susceptible anaerobic bacteria.
From January to May of this year, Shijiazhuang Sihua Pharmaceutical Group has achieved remarkable success in scientific research and development. To date, a total of 16 new product projects have been approved, and 24 projects have been submitted one after another. Once these innovative achievements are approved and put into production, they will continuously inject new momentum into the company’s high-quality development, strongly promoting the integrated and sustained development of the company’s innovation chain and product chain. This will also play a significant role in boosting market vitality and facilitating the optimization and upgrading of the company’s product structure.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license